Chief Executive Officer

Chief Financial Officer

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

Disc Medicine names Lisa Amaya Price as Chief Human Resources Officer

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference

0.6000000238418579

Senior Manager, Submission Management & Regulatory Operations

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing novel treatments for hematologic diseases. The Senior Manager, Submission Management & Regulatory Operations will oversee the management and coordination of regulatory submissions, ensuring compliance and effective communication with project teams and external partners.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing novel treatments for hematologic diseases. They are seeking a Senior Manager for Submission Management & Regulatory Operations to oversee regulatory submissions, maintain compliance, and support project teams in a dynamic hybrid work environment.

Chairman & CEO

Vice President Corporate Communications

Alaska settles 2 lawsuits against vape companies for allegedly targeting kids for addiction

Altria Invests $12.8 Billion in E-Cigarette Maker Juul

LTRIA MAKES $12.8 BILLION MINORITY INVESTMENT IN JUUL TO ACCELERATE HARM REDUCTION AND DRIVE GROWTH

Juul of denial: castigated vaping brand aims to defy ruin with age assurance tech

0.4000000059604645

Manager, Regulatory Submissions

Juul Labs is focused on transitioning adult smokers away from combustible cigarettes and addressing underage usage through innovation and quality. The Manager, Regulatory Submissions will support major product regulatory filings to the U.S. FDA and collaborate with various stakeholders to ensure compliance and strategic alignment in the submission process.

President & CEO

Chief Operating Officer and Chief Business Officer

Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)

Kailera Therapeutics Appoints Doug Pagán as Chief Financial Officer

Kailera Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Here’s what happened to Mass. startup investing in 2025

Director, Global Regulatory Affairs (Submission Project Management)

Kailera is committed to developing therapies that empower individuals to transform their lives and improve their health. The Director of Global Regulatory Affairs will lead cross-functional teams in the planning and execution of compliant marketing authorization filings to support product approvals and organizational growth.